id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10172 R46498 |
Blotière (Phenobarbital) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Oro-facial clefts | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
4.18 [0.22;78.35] C excluded (control group) |
0/80 4/2,997 | 4 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10042 R46489 |
Blotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 | Oro-facial clefts | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 4.18 [0.26;67.49] C | 0/80 2,815/1,875,733 | 2,815 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9151 R31459 |
Tomson (Phenobarbital), 2018 | Cleft lip or palate | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.86 [0.30;27.55] C | 1/294 3/2,514 | 4 | 294 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9118 R31329 |
Veiby (Phenobarbital) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 | Orofacial clefts | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick | Adjustment: No | 10.46 [0.42;262.81] C | 0/27 1/833 | 1 | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9107 R31285 |
Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 | Oral clefts | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 4.56 [1.32;15.71] C | 4/199 7/1,562 | 11 | 199 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 4.46 [1.70;11.72] | 2,831 | 600 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital) (Controls unexposed NOS) (Mixed indications; 2: Phenobarbital; 3: Phenobarbital) (Controls exposed to Lamotrigine, sick) (Mixed indications; 4: Phenobarbital) (Controls exposed to Lamotrigine, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 10172